Table 2.
Variables | na | Good response (%) | Poor response (%) | P value | |
---|---|---|---|---|---|
Age | <65 | 8 | 5 (63) | 3 (78) | 0.08 |
≥65 | 20 | 5 (25) | 15 (75) | ||
Sex | Male | 18 | 8 (44) | 10 (56) | 0.41 |
Female | 10 | 2 (20) | 8 (80) | ||
Tumor histology | Adenocarcinoma | 6 | 2 (33) | 4 (67) | 1.00 |
Non-adenocarcinoma | 22 | 8 (36) | 14 (64) | ||
Clinical stage | III | 7 | 4 (57) | 3 (43) | 0.19 |
IV | 21 | 6 (29) | 15 (71) | ||
Performance status | 0/1 | 26 | 10 (38) | 16 (62) | 0.53 |
2 | 2 | 0 (0) | 2 (100) | ||
Smoking status | Never | 4 | 0 (0) | 4 (100) | 0.27 |
Ever | 24 | 10 (42) | 14 (58) | ||
CTR1 | High | 11 | 7 (64) | 4 (36) | 0.02b |
Low | 17 | 3 (18) | 14 (82) | ||
TS | High | 15 | 3 (20) | 12 (80) | 0.06 |
Low | 13 | 7 (54) | 6 (46) | ||
CTR1/TS | Either CTR1High or TSLow | 20 | 10 (50) | 10 (50) | 0.01b |
Both CTR1Lowand TSHigh | 8 | 0 (0) | 8 (100) |
Tumor response was evaluable in 28 of the 29 patients;
Statistically significant; CTR1, copper transporter 1; NSCLC, non-small cell lung cancer; TS, thymidylate synthase